Nifty
:
23547.75
Sensex
:
74775.74
-359.40 (-1.50%)
-1092.06 (-1.44%)
Nifty
Sensex
:
:
23547.75
74775.74
-359.40 (-1.50%)
-1092.06 (-1.44%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 532531 | NSE: STAR

NSE BSE
1111.80
29-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1157.7
  •  1168.8
  •  1089
  •  1154.40
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  519082
  •  585332967.2
  •  1231
  •  768.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,223.34
  • 18.38
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,678.88
  • 0.45%
  • 3.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 27.91%
  • 3.97%
  • 20.78%
  • FII
  • DII
  • Others
  • 28.68%
  • 13.11%
  • 5.55%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.78
  • 6.60
  • 7.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.78
  • 4.94
  • 15.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 9.76
  • 132.95

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.10
  • -
  • 2.23

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.25
  • 2.53
  • 3.19

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.49
  • 15.56
  • 11.70

Earnings Forecasts:

(Updated: 30-05-2026)
Description
2024
2025
2026
2027
Adj EPS
62.3
68
100.7
P/E Ratio
17.85
16.35
11.04
Revenue
4862.2
5808
7090.6
EBITDA
930
1114
1469.9
Net Income
574.4
626.6
928.6
ROA
P/B Ratio
3.28
2.77
2.25
ROE
20.1
18.3
22.5
FCFF
424.8
480.5
656.5
FCFF Yield
3.4
3.84
5.25
Net Debt
BVPS
339.35
401.83
493.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
1,323.47
1,190.39
11.18%
1,194.65
1,153.67
3.55%
1,220.83
1,166.93
4.62%
1,119.74
1,054.34
6.20%
Expenses
1,083.76
972.52
11.44%
958.70
943.35
1.63%
989.26
982.33
0.71%
901.66
864.31
4.32%
EBITDA
239.71
217.87
10.02%
235.94
210.31
12.19%
231.57
184.60
25.44%
218.07
190.03
14.76%
EBIDTM
18.11%
18.30%
19.75%
18.23%
18.97%
15.82%
19.48%
18.02%
Other Income
8.13
11.98
-32.14%
106.86
5.62
1,801.42%
27.14
28.41
-4.47%
8.58
12.72
-32.55%
Interest
41.58
50.32
-17.37%
43.38
52.18
-16.86%
46.13
73.82
-37.51%
47.46
72.52
-34.56%
Depreciation
53.25
48.86
8.98%
50.62
48.42
4.54%
49.64
48.45
2.46%
48.89
46.52
5.09%
PBT
146.60
103.25
41.99%
245.51
112.89
117.48%
154.17
86.87
77.47%
121.94
182.07
-33.03%
Tax
18.77
20.76
-9.59%
37.35
23.80
56.93%
21.59
13.94
54.88%
16.45
19.02
-13.51%
PAT
127.83
82.49
54.96%
208.15
89.09
133.64%
132.57
72.93
81.78%
105.49
163.06
-35.31%
PATM
9.66%
6.93%
17.42%
7.72%
10.86%
6.25%
9.42%
15.47%
EPS
13.77
8.92
54.37%
21.93
9.54
129.87%
13.84
7.81
77.21%
10.81
364.62
-97.04%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
4,858.69
4,565.34
3,890.13
3,688.39
3,070.25
3,315.87
2,751.97
2,178.37
2,845.11
2,755.44
2,862.19
Net Sales Growth
6.43%
17.36%
5.47%
20.13%
-7.41%
20.49%
26.33%
-23.43%
3.25%
-3.73%
 
Cost Of Goods Sold
1,958.74
1,979.96
1,749.05
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
Gross Profit
2,899.95
2,585.37
2,141.07
2,061.50
1,567.93
1,983.08
1,629.49
1,093.18
1,466.28
1,474.27
1,359.90
GP Margin
59.69%
56.63%
55.04%
55.89%
51.07%
59.81%
59.21%
50.18%
51.54%
53.50%
47.51%
Total Expenditure
3,933.38
3,767.56
3,317.89
3,303.09
3,091.76
2,689.06
2,236.07
1,936.06
2,442.83
2,228.09
2,448.21
Power & Fuel Cost
-
58.17
75.13
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
% Of Sales
-
1.27%
1.93%
2.33%
2.33%
1.95%
2.34%
2.50%
1.80%
1.23%
2.70%
Employee Cost
-
862.76
737.05
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
% Of Sales
-
18.90%
18.95%
19.85%
21.07%
16.59%
16.08%
15.12%
15.26%
15.21%
12.50%
Manufacturing Exp.
-
311.98
299.81
259.45
255.52
237.94
210.79
150.98
141.97
145.40
127.91
% Of Sales
-
6.83%
7.71%
7.03%
8.32%
7.18%
7.66%
6.93%
4.99%
5.28%
4.47%
General & Admin Exp.
-
221.56
198.06
232.21
223.67
191.73
191.89
150.10
194.38
172.63
191.17
% Of Sales
-
4.85%
5.09%
6.30%
7.29%
5.78%
6.97%
6.89%
6.83%
6.27%
6.68%
Selling & Distn. Exp.
-
298.20
215.03
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
% Of Sales
-
6.53%
5.53%
7.15%
10.79%
6.73%
4.98%
5.11%
7.34%
5.85%
4.53%
Miscellaneous Exp.
-
34.93
43.76
103.06
60.51
88.65
66.79
54.74
33.41
14.74
129.57
% Of Sales
-
0.77%
1.12%
2.79%
1.97%
2.67%
2.43%
2.51%
1.17%
0.53%
2.18%
EBITDA
925.29
797.78
572.24
385.30
-21.51
626.81
515.90
242.31
402.28
527.35
413.98
EBITDA Margin
19.04%
17.47%
14.71%
10.45%
-0.70%
18.90%
18.75%
11.12%
14.14%
19.14%
14.46%
Other Income
150.71
63.76
49.85
135.22
133.40
59.44
53.11
40.84
88.32
161.08
92.10
Interest
178.55
248.85
280.22
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
Depreciation
202.40
192.26
213.64
243.25
233.01
206.29
173.70
117.39
154.03
126.15
131.25
PBT
668.22
420.42
128.22
16.11
-297.88
329.90
239.59
86.47
140.32
379.18
206.65
Tax
94.16
77.52
29.11
-55.30
-178.26
31.65
11.32
-26.86
5.68
63.41
42.45
Tax Rate
14.09%
15.98%
-47.86%
6010.87%
32.91%
8.48%
6.99%
-24.85%
5.87%
18.50%
25.68%
PAT
574.04
405.34
-120.20
-221.20
-460.21
254.50
49.16
83.99
54.39
233.51
131.68
PAT before Minority Interest
555.71
409.40
-143.90
-230.90
-474.25
243.79
43.36
89.25
74.26
279.71
118.15
Minority Interest
-18.33
-4.06
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
PAT Margin
11.81%
8.88%
-3.09%
-6.00%
-14.99%
7.68%
1.79%
3.86%
1.91%
8.47%
4.60%
PAT Growth
40.84%
-
-
-
-
417.70%
-41.47%
54.42%
-76.71%
77.33%
 
EPS
62.26
43.96
-13.04
-23.99
-49.91
27.60
5.33
9.11
5.90
25.33
14.28

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,551.83
2,125.57
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
Share Capital
92.16
91.90
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
Total Reserves
2,459.16
2,030.57
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
Non-Current Liabilities
601.61
621.44
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
Secured Loans
558.47
618.40
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
Unsecured Loans
12.78
53.10
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
Long Term Provisions
113.94
91.63
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
Current Liabilities
2,591.52
2,879.26
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,896.17
3,103.87
1,891.98
Trade Payables
1,032.50
851.59
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
Other Current Liabilities
307.41
341.57
527.89
697.18
421.00
354.49
248.12
126.85
819.08
347.93
Short Term Borrowings
1,136.36
1,574.15
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
Short Term Provisions
115.25
111.94
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
Total Liabilities
5,779.59
5,572.41
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,581.77
8,034.86
7,360.09
Net Block
1,888.12
1,853.18
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
Gross Block
2,897.25
2,873.18
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
Accumulated Depreciation
1,009.14
1,020.00
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
Non Current Assets
2,680.68
2,603.41
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
Capital Work in Progress
206.76
161.89
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
Non Current Investment
339.71
196.93
438.96
540.34
598.00
430.44
416.97
276.50
245.06
52.50
Long Term Loans & Adv.
140.19
256.13
217.18
210.58
187.83
214.69
227.76
206.54
222.69
201.97
Other Non Current Assets
94.73
123.38
11.91
10.26
547.00
424.33
12.78
21.40
15.48
22.49
Current Assets
3,098.91
2,969.00
3,135.25
3,361.83
2,817.23
2,370.61
3,048.72
2,446.53
3,791.82
3,514.89
Current Investments
69.50
105.76
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
Inventories
1,277.57
1,126.24
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
Sundry Debtors
1,202.94
1,141.87
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
Cash & Bank
136.78
191.17
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
Other Current Assets
412.12
228.99
169.21
647.90
226.76
300.31
385.98
397.52
454.10
343.44
Short Term Loans & Adv.
135.92
174.97
153.34
145.49
128.54
218.24
249.11
311.71
245.26
229.85
Net Current Assets
507.39
89.74
145.05
-49.84
78.89
-174.25
386.48
550.36
687.95
1,622.91
Total Assets
5,779.59
5,572.41
6,265.28
6,760.71
6,816.80
5,951.66
7,806.77
6,547.84
8,034.87
7,360.09

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
684.37
701.07
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
PBT
3,675.03
-62.72
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
Adjustment
-2,893.97
818.27
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
Changes in Working Capital
-163.72
-78.73
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
Cash after chg. in Working capital
617.34
676.82
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
67.04
24.25
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-89.69
-150.25
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
Net Fixed Assets
-32.00
-315.30
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
Net Investments
515.90
128.18
-92.01
-5.11
-224.10
-21.67
-372.21
743.57
-147.22
-1,404.56
Others
-573.59
36.87
448.48
-52.03
-209.97
1,494.89
272.21
-838.18
-302.81
-284.34
Cash from Financing Activity
-642.58
-693.32
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
Net Cash Inflow / Outflow
-47.90
-142.51
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
Opening Cash & Equivalents
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
Closing Cash & Equivalent
112.56
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
276.83
230.95
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
ROA
7.21%
-2.41%
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
ROE
17.52%
-6.67%
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
ROCE
16.56%
3.47%
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
Fixed Asset Turnover
2.46
1.96
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
Receivable days
60.35
73.17
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
Inventory Days
61.86
68.12
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
Payable days
173.66
191.36
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
Cash Conversion Cycle
-51.45
-50.07
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
Total Debt/Equity
0.70
1.14
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
Interest Cover
2.96
0.59
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Strides Pharma’s Bangalore facility receives five observations from USFDA
    21st May 2026, 14:11 PM

    The USFDA had conducted a routine current cGMP inspection at the facility during the period from May 12, 2026 to May 20, 2026

    Read More
  • Strides Pharma Scien - Quarterly Results
    19th May 2026, 00:00 AM

    Read More
  • Strides Pharma's arm inks pact with Sandoz to acquire branded generics portfolio in SSA
    18th Mar 2026, 09:17 AM

    The initial consideration for the transaction is $12 million, payable at closing

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.